Dr. Francissen has been dedicated to the development of advanced therapy medicinal products (ATMP) for the past several years, thus leveraging >25 years of experience in biopharmaceutical development. She serves as the Rapporteur of the ICH CGT DG, representing the Biotechnology Innovation Organization (BIO), and is responsible for leading the technical discussions.